The current financial score of Skye Bioscience Inc is 7.00. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Skye Bioscience Inc is 9.61. Its current P/E ratio is -1.23, which is -973.38% below the recent high of 10.76 and -318.16% above the recent low of -5.15.
The current earnings forecast score of Skye Bioscience Inc is 7.20. The average price target is 64.00, with a high of 160.00 and a low of 16.00.
The current price momentum score of Skye Bioscience Inc is 5.82. Currently, the stock price is trading between the resistance level at 2.23 and the support level at 1.41, making it suitable for range-bound swing trading.
The current institutional shareholding score of Skye Bioscience Inc is 3.00. The latest institutional shareholding proportion is 48.44%, representing a quarter-over-quarter decrease of 22.80%.
The current risk assessment score of Skye Bioscience Inc is 1.41. The company's beta value is 2.99. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.